EU Regulators Contradict Germany's Assessment Of Pfizer Anti-Depressant
Executive SummaryA recent ruling by the European Medicines Agency that the benefit-risk profile of Pfizer Inc.'s antidepressant Endronax (reboxetine) was positive contradicts the outcome of a similar assessment a year ago by German health technology assessment body IQWiG, which had rubbished the drug as “ineffective and potentially harmful.” But it’s far from clear that Pfizer will now have any chance to resurrect the drug in Germany, however.
You may also be interested in...
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.